23. An Introduction to Biologics

Ian Mullaney

School of Pharmacy, Faculty of Health Sciences, Murdoch University, Murdoch, WA6150, Australia.

Phone +61 8 93601236 Fax +61 8 93601240 Email i.mullaney@murdoch.edu.au

Reviewed by Sheila Doggrell, Queensland University of Technology

Key words: Biologics, recombinant proteins/hormones, genetic engineering, monoclonal antibody, protein vaccines, erythropoietin, tenectaplase, immunoglobulins, muromonab-CD3, infliximab, alemtuzumab, abciximab, trastuzumab, rituximab, basiliximab, ozogamycin, mafenatox, brentuximab vedotin, ibritumomab tiuextan, Gardasil

Contents

23. An introduction to biologics

23.1 Introduction: Principles of biologics and their use as medicines

23.2 Protein biologics used as drugs

23.2.1 Proteins that function through enzymatic or regulatory activity.

23.2.1.1 Biologics as replacement of a deficient or abnormal protein.

23.2.1.2 Proteins that augment an existing biological process.

23.2.1.3 Proteins that provide a novel function or activity.

23.2.2. Proteins that function through specific targeting activity.

23.2.2.1. Monoclonal antibody nomenclature.

23.2.2.2. Naked monoclonal antibodies.

23.2.2.3. Conjugated monoclonal antibodies.

23.2.3. Recombinant protein vaccines.